• Explore /
  • Poster
  • / Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.

Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.

Abstract Poster

Authors

null

Nadezhda Omelchenko

Sarcoma Oncology Research Center, Santa Monica, CA

Nadezhda Omelchenko , Neal Shiv Chawla , Stefan Makrievski , Guilherme Leao De Melo , Chrysler Valencia , Amir Ahari , Ania Moradkhani , Victoria Chua , Doris Quon , Don Arlen Brigham , Sant P. Chawla , Erlinda Maria Gordon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT04535713

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11555)

DOI

10.1200/JCO.2023.41.16_suppl.11555

Abstract #

11555

Poster Bd #

489

Abstract Disclosures

Similar Posters

First Author: Noufil Adnan

First Author: Geoffrey Thomas Gibney

First Author: Ghazal Tansir

First Author: Makoto Endo